An observational study in NASH and NAFLD, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy — 21 open to participants now, 29 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Italy.
Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, this one is the 10th largest by planned enrollment of the 24 observational ones that give a count, is one of 2 that started in 2025, is one of 24 observational ones, reaches primary completion later than 12 of the 28 other live ones, and was the 95th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →21 of the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy are open now. Recruiting first, the newest first:
University of Palermo · Sites in Italy
Ages 1–14
Eli Lilly and Company · Sites in Italy, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Italy, United States, Argentina and 20 more countries
Ages 18–80
The Cleveland Clinic · Sites in Italy, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
Hoffmann-La Roche · Sites in Italy, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 24 · Phase 3 19 · Phase 4 2
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 252 is above the median of 152 across 391 observational studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 150 across the 75 interventional studies, 136 across the 24 observational. Of the 55 that completed or were terminated, 25 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 99 have an industry lead sponsor. The 10 most frequent:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 6 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Non-alcoholic Fatty Liver Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06537466University of PalermoKetogenic Diet in MASLD-related cACLD | 2026-11 |
| NCT06888310Fondazione Policlinico Universitario Agostino Gemelli IRCCSOptimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease | 2026-12-01 |
| NCT06879236Fondazione Policlinico Universitario Agostino Gemelli IRCCSSecondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease | 2026-12-14 |
| NCT07644936Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisMolecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of cirrhosis, hepatocellular carcinoma (HCC), and the need for liver transplantation. Due to the lack of noticeable symptoms during the early stages, the detection of MASLD is often delayed until the disease has advanced.
Currently, the treatment options MASLD are limited to lifestyle interventions such as dietary changes and physical activity. Despite the increasing prevalence of MASLD, there are no drugs available on the market specifically for this condition.
The goal is to made new model care which integrates the standard clinical procedures with a digital approach, namely a mobile application for patients and a clinical dashboard for healthcare professionals (HCPs), integrated with simple clinical data (anthropometric, laboratory and imaging data).
This study wants to test the feasibility of integrating a digital intervention to improve the patient engagement and linkage to care in order to identify the advanced MASLD at earliest stage (secondary prevention) and mitigate the impact of ongoing advanced liver disease helping patients to manage the long-term effect of disease.
To achieve this goal the study will leverage on a mobile app named OpenTele in order to test the adherence to lifestyle changes in patient with MASLD and on the connected clinical dashboard.
The app aims at integrating the standard clinical practice with digital technologies able to guide and support patients in order to seamlessly integrate secondary prevention strategies in their everyday life with 2 main aims:
subjects with type 2 diabetes and/or metabolic syndrome and/or dyslipidemia and/or obesity (BMI>30 Kg/m2) and/or familiar history for cirrhosis or liver cancer in the absence of known risk factors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
App Adherence (>80% over 4 weeks)
Assessed via smartphone (number of app access)
Time frame: 4 weeks
Weight reduction assessment
Number of subjects with a 12-month reduction between 7-10% of weight compared to baseline
Time frame: 12 month
Change in liver and spleen stiffness
Assessed by transient elastography
Time frame: Baseline, after 4 weeks and 12 month
Change in Patient Reported Outcome questionnaire
Evaluation of overall physical well-being through the administration of questionnaires
Time frame: 12 weeks
Changes in measure energy expenditure
Cycle ergometer
Time frame: 12 month
Microbiome signature
Analysis of microbiome signature from feces
Time frame: 12 month
Clinical events
Record of number of hospitalization, decompensation, variceal bleeding, encephalopathy, ascites, liver cancer, liver transplantation, death
Time frame: 12 month
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's planned 22 months is below that.
Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →